Context Therapeutics Inc. (CNTX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Martin A. Lehr
|
Co-Founder, President, CEO & Director | 914.01k | -- | 1984 |
|
Ms. Jennifer Minai-Azary
|
CFO & Treasurer | 610.73k | -- | 1978 |
|
Mr. Alex C. Levit Esq., J.D.
|
Chief Legal Officer & Corporate Secretary | 576.31k | -- | 1979 |
|
Mr. Christopher Beck M.B.A.
|
Senior Vice President of Operations | -- | -- | -- |
|
Mr. Jeffrey Liebman
|
Associate Director of Accounting | -- | -- | -- |
|
Ms. Jennifer Dashnau M.B.A., Ph.D.
|
Senior Vice President of Technical Operations | -- | -- | -- |
|
Dr. Karen Chagin M.D.
|
Chief Medical Officer | -- | -- | 1977 |
Context Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 15
Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
